Gregg Klofenstine’s Post

Visit our YouTube channel at the link below to watch an exciting excerpt from yesterday's ICARE Genetics Case Conference, during which Diane Koeller, MS, MPH, CGC (she/her/hers) presents on EGFR and the INHERIT Study 🧬 ⤸ https://lnkd.in/gtRJ_dYn #ICARE #InheritedCancerRegistry #InheritedCancer #HereditaryCancer #Cancer #Genetics #CancerGenetics #GeneticTesting #EGFR #INHERITstudy #CancerRisks #GeneticsWebinar #CancerEducation #CancerResearch

Creating universal hypoimmunogenic iPSC through selective knock out! For allogeneic transplantation purpose iPSC’s need to be configured to prevent mismatching and rejection by the immune system, e.g. through NK cells. Functional validation of successful genetic engineering is realized by #SimpleWestern technology at the protein level.   Check out the groundbreaking application: https://lnkd.in/efKdgb-J #iPCS #CGT #Genetherapy #Celltherapy

TransCelerate webinar on master protocols is coming up. Short history on the topic is summarized here :-)

🌟 🚀Memorial Sloan Kettering Innovation Hub Challenge – Now Accepting Applications! 🚀 🌟 Exciting news! Applications for the first-ever Memorial Sloan Kettering Innovation Hub Challenge are now open! The theme for this cohort is Decentralized Clinical Trials. This is a great opportunity to join a dynamic community dedicated to revolutionizing cancer care through digital health innovation. Spread the word, share, repost and tag digital health teams who could benefit from this program! -- ℹ What is the MSK Innovation Hub Challenge? The MSK Innovation Hub Challenge (MSK iHub Challenge) was launched in 2024 as an expansion of MSK’s successful Innovation Hub program- a digital health accelerator which unites clinicians, researchers, and healthcare technology developers to create solutions that advance the prevention and treatment of cancer, positively impacting patients' lives. In twice-yearly sessions, the MSK iHub Challenge will welcome a cohort of digital healthcare companies focusing on strategic themes identified by MSK’s clinical and digital health experts as areas of need and opportunity within the global healthcare sector. Our goal is to help jumpstart digital health innovation aimed at achieving transformative results. ℹ MSK iHub Challenge: Decentralized Clinical Trials For this cohort, we are seeking digitally focused companies committed to making a meaningful impact in enabling clinical trials to take place closer to where patients are, including where they live and/or work. Companies can interpret this expansively to include tools, processes, and resources that reduce patient, clinical, and operational burden and overcome barriers to accessing and running decentralized clinical trials in a hybrid, virtual, or digitized model. We are excited to work with companies that specialize in cancer care or those that might be ready to adapt to meet the unique challenges of this critical area. ➡ Apply now and learn more here: https://lnkd.in/gn6iunp3

Could this be a shared vision for the global community of change angels? Creating a world that is fit for the next 7 generations to live and flourish in… Native American tribes hold dear the concept of seven generations planning, that the impact of decisions should be considered out seven generations into the future, about 150 years. The idea is that our decisions today should consider the potential benefits or harm that would be felt by seven future generations. While such future-thinking has obvious ethical and moral value, it seems that it may also have scientific validity. Scientific Evidence to Support 'Seven Generations' Future Thinking We should listen to the elders way more often ! Learn from ancient wisdom

Reciprocal translocation explained Reciprocal translocation is a chromosome abnormality caused by exchange of parts between non-homologous chromosomes. Two detached fragments of two different chromosomes are switched. In genetics, chromosome translocation is a phenomenon that results in unusual rearrangement of chromosomes. This includes balanced and unbalanced translocation, with two main types: reciprocal-, and Robertsonian translocation. Reciprocal translocation is a chromosome abnormality caused by exchange of parts between non-homologous chromosomes. Two detached fragments of two different chromosomes are switched. Robertsonian translocation occurs when two non-homologous chromosomes get attached, meaning that given two healthy pairs of chromosomes, one of each pair "sticks" together. A gene fusion may be created when the translocation joins two otherwise-separated genes. It is detected on cytogenetics or a karyotype of affected cells. Translocations can be balanced \(in an even exchange of material with no genetic information extra or missing, and ideally full functionality\) or unbalanced \(where the exchange of chromosome material is unequal resulting in extra or missing genes\). Reciprocal translocations are usually an exchange of material between non-homologous chromosomes. Estimates of incidence range from about 1 in 500 to 1 in 625 human newborns. Such translocations are usually harmless and may be found through prenatal diagnosis. However, carriers of balanced reciprocal translocations have increased risks of creating gametes with unbalanced chromosome translocations, leading to Infertility, miscarriages or children with abnormalities. Genetic counseling and genetic testing are often offered to families that may carry a translocation. Most balanced translocation carriers are healthy and do not have any symptoms. It is important to distinguish between chromosomal translocations occurring in gametogenesis, due to errors in meiosis, and translocations that occur in cellular division of somatic cells, due to errors in mitosis. The former results in a chromosomal abnormality featured in all cells of the offspring, as in translocation carriers. Somatic translocations, on the other hand, result in abnormalities featured only in the affected cell line, as in chronic myelogenous leukemia with the Philadelphia chromosome translocation. Youtube video: https://lnkd.in/d9EQNr7z \#nikolays_genetics_lessons

Our bi-monthly column curating the most widely read content published in our partner journal, the Journal of Comparative Effectiveness Research. Here we select the top-read articles in March–April 2024. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata

🎙️ Introducing Dr Ron Hargreaves, a PhD chemist who was part of the Lederle Laboratories team that developed chemotherapy compounds, including #bisantrene. In this exclusive interview, Dr Hargreaves discusses his involvement in bisantrene's origins at Lederle Laboratories, its potential as an oncology agent, and why it wasn’t marketed at the time. Now, with renewed interest and promising clinical results, bisantrene lives on as a potential #anticancer treatment. 🔗 Watch the full interview here: https://lnkd.in/gCerUEBt #OncologyResearch #CancerTreatment #cardioprotection

I am excited to share that my paper titled "Experiences of men undergoing prostate cancer screening at a hospital in Gauteng, South Africa" has been published. https://lnkd.in/g73jGfmU